ScreenerHero

MNOVMediciNova, Inc.

NAS · US · Healthcare · Biotechnology · medicinova.com
1.390USD+0.72%Mkt Cap: 68.42M $P/E: —

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilas…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap68.42M $
Enterprise Value42.13M $
Revenue (TTM)920.48K $
Gross Profit31.05K $
Net Income (TTM)-12.00M $
Revenue/Share0.0190 USD
Last Price1.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.04
PEG—
EV/EBITDA-3.56
EV/Revenue45.77
P/S73.26
P/B1.81
EPS (TTM)-0.21
EPS (Forward)-0.45
52W Range
1.17028% of range1.960
52W High1.960 USD
52W Low1.170 USD
Profitability
Gross Margin7.58%
Oper. Margin-554.31%
EBITDA Margin0.00%
Profit Margin-2928.78%
ROE-28.85%
ROA-26.31%
Growth
Revenue Growth240.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.81M $
CapEx (TTM)2.90K $
FCF Margin-623.47%
FCF Yield-8.39%
Net Debt-25.30M $
Net Debt/EBITDA2.14
Balance Sheet
Debt/Equity0.00
Current Ratio8.75
Quick Ratio8.58
Book Value/Sh0.7570 USD
Cash/Share0.5160 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.000 USD
Upside (mean)+547.5%
Target Range6.000 USD – 11.00 USD
$6.000+547.5% to mean$11.00
# Analysts3
Ownership
Shares Out.49.22M
Float42.26M
Insiders2.88%
Institutions10.58%
Short Interest
Short Ratio6.4d
Short % Float0.72%
Short % Out.0.70%
Shares Short346.44K
Short (prev mo.)204.81K
Technical
SMA 501.339 (+3.8%)
SMA 2001.428 (-2.7%)
Beta0.62
S&P 52W Chg18.16%
Avg Vol (30d)35.49K
Avg Vol (10d)32.36K
Technical Indicators
RSI (14)59.6
MACD0.0019
MACD Signal-0.0047
MACD Hist.+0.0066
BB Upper1.378 USD
BB Middle1.329 USD
BB Lower1.280 USD
BB Width7.37%
ATR (14)0.0479 USD
Vol Ratio (20d)0.84x